Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 29,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin; Drug
Lead sponsor: Synthekine; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 35
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 28 more

Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Interventions: Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous), Mesna; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sarcoma
Interventions: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim; Drug · Procedure · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Hydrocortisone; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: Prednisolone high dose, Prednisolone lower dose; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HER2-expressing Cancers
Interventions: ZW49; Drug
Lead sponsor: Zymeworks BC Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Neoplasms
Interventions: BI 905681; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Sarasota, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more

Conditions: Hepatitis, Chronic, Hepatitis C Virus
Interventions: Small Molecule Agent (PF-868554); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sarcoma, Soft Tissue
Interventions: BLZ-100; Drug
Lead sponsor: Blaze Bioscience Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Covid19
Interventions: C144-LS and C-135-LS; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease, Sarcopenia, Frailty
Interventions: CoQ10, Nicotinamide riboside, Placebo; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 30 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia
Interventions: ALT-803; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Postoperative Pain
Interventions: Fentanyl, Ketorolac, Nerve of Arnold Block, Sham Intramuscular Injection, Sham Nerve of Arnold Block, Dexmedetomidine, Bupivacaine; Drug · Procedure
Lead sponsor: University of South Alabama; Other
Eligibility: 6 Months to 6 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Interventions: CTX131; Biological
Lead sponsor: CRISPR Therapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions: MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood; Biological · Procedure · Radiation + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, Radiation therapy; Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Norovirus Infection
Interventions: Norwalk GI.1 Virus; Biological
Lead sponsor: WCCT Global; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04603629, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more

Conditions: Healthy Volunteers
Interventions: INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG); Biological · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Cancer
Interventions: erlotinib hydrochloride, sunitinib malate, biopsy; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Portland, Oregon • Salem, Oregon

Conditions: Opioid Overdose
Interventions: Nalmefene Hydrochloride; Drug
Lead sponsor: Opiant Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Search by objective public record fields.

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Hydrocortisone for Prevention of Post-Traumatic Stress Disorder

Oral Prednisolone Dosing in Children Hospitalized With Asthma

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers

Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold (NOA) Block for Bilateral Myringotomy

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines